Form 4: Avidity Biosciences Officer Sells Shares in Novartis Merger

Avidity Biosciences' Chief Program Officer, Kathleen P. Gallagher, disposed of all her common stock and stock options as part of the merger agreement with Novartis AG.

Summary

• Kathleen P. Gallagher, Chief Program Officer of Avidity Biosciences, Inc., disposed of all her beneficial ownership in the company.
• This disposal included 80,303 shares of common stock and 208,330 stock options.
• The transactions occurred on February 27, 2026.
• The disposal was executed pursuant to the Agreement and Plan of Merger, dated October 25, 2025, between Avidity Biosciences, Novartis AG, and Ajax Acquisition Sub, Inc.
• Common stock was disposed of as part of the merger terms.
• Stock options were exchanged for a cash payment equal to the merger consideration of $72.00 per share minus their respective exercise prices.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development for Avidity Biosciences' shareholders and equity holders, as the merger with Novartis AG at a $72.00 per share consideration represents a successful exit and value realization.

Positives

• The disposal of shares and options is a direct result of a merger agreement with Novartis AG, indicating a successful acquisition for Avidity Biosciences shareholders.
• The merger consideration of $72.00 per share for options exceeding their exercise price suggests a premium for option holders, leading to a profitable cash payout.

Future Outlook

The filing, a Form 4, reports a completed insider transaction resulting from a merger and does not provide forward-looking statements or guidance regarding Avidity Biosciences' future operations as an independent entity.

Industry Context

StockSavvy.ai notes that this Form 4 filing signals the final stages of Avidity Biosciences' acquisition by Novartis AG, a common strategy in the pharmaceutical and biotechnology sectors for larger companies to integrate promising assets or technologies. This transaction reflects ongoing consolidation trends where established pharmaceutical giants seek to bolster their pipelines through strategic M&A.

Comparison to Industry Standards

• The merger consideration of $72.00 per share for Avidity Biosciences (RNAM) can be contextualized against other recent biotech acquisitions. For instance, Pfizer's acquisition of Seagen for $43 billion ($229 per share) in 2023 or Merck's acquisition of Prometheus Biosciences for $10.8 billion ($200 per share) in 2023. While the absolute per-share value varies based on company size and stage, the premium paid over the pre-announcement price is a critical metric for evaluating such deals.
• The mechanism for option payouts, where holders receive the difference between the merger consideration and the exercise price, is a standard and widely accepted practice in M&A transactions, ensuring that option holders benefit from the acquisition's value.

Management Changes

Stakeholder Impact

• Shareholders: Realization of value at $72.00 per share through the merger with Novartis AG.
• Employees (holding options): Received cash payouts for in-the-money options, indicating a financial benefit from the acquisition.

Key Dates

Keywords

Avidity Biosciences, RNAM, Novartis AG, Merger Agreement, Form 4, Insider Transaction, Stock Options, Common Stock, Acquisition, Kathleen P. Gallagher